Wall Street brokerages expect that Antares Pharma, Inc. (NASDAQ:ATRS) will report earnings of ($0.03) per share for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Antares Pharma’s earnings, with the highest EPS estimate coming in at ($0.01) and the lowest estimate coming in at ($0.04). Antares Pharma also reported earnings of ($0.03) per share during the same quarter last year. The company is expected to report its next quarterly earnings results on Tuesday, March 13th.
According to Zacks, analysts expect that Antares Pharma will report full-year earnings of ($0.11) per share for the current year, with EPS estimates ranging from ($0.12) to ($0.10). For the next financial year, analysts anticipate that the company will post earnings of $0.00 per share, with EPS estimates ranging from ($0.11) to $0.18. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for Antares Pharma.
Antares Pharma (NASDAQ:ATRS) last posted its earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.03). The business had revenue of $15.10 million for the quarter, compared to analyst estimates of $14.01 million. Antares Pharma had a negative net margin of 32.06% and a negative return on equity of 43.05%. The business’s revenue for the quarter was up 11.9% compared to the same quarter last year.
A number of analysts recently weighed in on the stock. HC Wainwright set a $5.00 target price on shares of Antares Pharma and gave the stock a “buy” rating in a report on Friday, October 13th. Piper Jaffray Companies set a $3.00 target price on shares of Antares Pharma and gave the stock a “buy” rating in a report on Monday, October 23rd. ValuEngine lowered shares of Antares Pharma from a “hold” rating to a “sell” rating in a report on Monday, October 16th. Finally, BidaskClub raised shares of Antares Pharma from a “hold” rating to a “buy” rating in a report on Friday, December 22nd. One research analyst has rated the stock with a sell rating, four have given a buy rating and two have issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $3.84.
A number of hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in Antares Pharma by 10.1% in the 2nd quarter. Vanguard Group Inc. now owns 6,186,232 shares of the specialty pharmaceutical company’s stock worth $19,920,000 after buying an additional 567,144 shares in the last quarter. Perceptive Advisors LLC grew its stake in Antares Pharma by 2.0% in the 3rd quarter. Perceptive Advisors LLC now owns 4,353,897 shares of the specialty pharmaceutical company’s stock worth $14,107,000 after buying an additional 86,644 shares in the last quarter. State Street Corp grew its stake in Antares Pharma by 2,682.1% in the 2nd quarter. State Street Corp now owns 2,027,650 shares of the specialty pharmaceutical company’s stock worth $6,530,000 after buying an additional 1,954,769 shares in the last quarter. Northern Trust Corp grew its stake in Antares Pharma by 478.1% in the 2nd quarter. Northern Trust Corp now owns 1,654,266 shares of the specialty pharmaceutical company’s stock worth $5,327,000 after buying an additional 1,368,131 shares in the last quarter. Finally, Wells Fargo & Company MN grew its stake in Antares Pharma by 28.3% in the 3rd quarter. Wells Fargo & Company MN now owns 1,335,906 shares of the specialty pharmaceutical company’s stock worth $4,328,000 after buying an additional 294,810 shares in the last quarter. 34.63% of the stock is owned by institutional investors and hedge funds.
Antares Pharma (NASDAQ:ATRS) traded up $0.01 during trading on Thursday, reaching $2.23. 977,900 shares of the company were exchanged, compared to its average volume of 1,085,155. The company has a quick ratio of 2.89, a current ratio of 3.34 and a debt-to-equity ratio of 0.69. The company has a market cap of $342.53, a price-to-earnings ratio of -20.27 and a beta of 0.25. Antares Pharma has a twelve month low of $1.58 and a twelve month high of $4.09.
TRADEMARK VIOLATION WARNING: “Zacks: Brokerages Expect Antares Pharma, Inc. (ATRS) to Announce -$0.03 Earnings Per Share” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/18/zacks-brokerages-expect-antares-pharma-inc-atrs-to-announce-0-03-earnings-per-share.html.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.
Get a free copy of the Zacks research report on Antares Pharma (ATRS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.